Cargando…
Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction
We examined clinical outcomes with proton pump inhibitors (PPI) use within CYP2C19 genotype groups during clopidogrel treatment following acute myocardial infarction (AMI). 2062 patients were genotyped for CYP2C19*2 and *17 variants in TRIUMPH. 12 month clinical outcomes were analyzed among patients...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287459/ https://www.ncbi.nlm.nih.gov/pubmed/25001880 http://dx.doi.org/10.1038/tpj.2014.28 |
_version_ | 1782351789722435584 |
---|---|
author | Depta, Jeremiah P. Lenzini, Petra A. Lanfear, David E. Wang, Tracy Y. Spertus, John A. Bach, Richard G. Cresci, Sharon |
author_facet | Depta, Jeremiah P. Lenzini, Petra A. Lanfear, David E. Wang, Tracy Y. Spertus, John A. Bach, Richard G. Cresci, Sharon |
author_sort | Depta, Jeremiah P. |
collection | PubMed |
description | We examined clinical outcomes with proton pump inhibitors (PPI) use within CYP2C19 genotype groups during clopidogrel treatment following acute myocardial infarction (AMI). 2062 patients were genotyped for CYP2C19*2 and *17 variants in TRIUMPH. 12 month clinical outcomes were analyzed among patients discharged on clopidogrel within CYP2C19*2 carrier, CYP2C19*17 carrier, and CYP2C19*1 homozygote genotype groups. PPI use was not associated with a difference in mortality. Among clopidogrel-treated Caucasians following AMI, PPI use was associated with a significantly higher rate of cardiac rehospitalization (HR 1.62, 95% CI 1.19-2.19; p = 0.002) compared with no PPI use. PPI users who were carriers of the CYP2C19*17 variant experienced significantly higher rates of cardiac rehospitalization (HR 2.05, 95% CI 1.26-3.33; p = 0.003), carriers of the CYP2C19*2 variant had a trend toward increased 1-year cardiac rehospitalization (HR 1.69, 95% CI 0.95-2.99; P=0.07) while no significant differences were observed among CYP2C19*1 homozygotes. These results indicate that the risks associated with PPI use among clopidogrel-treated Caucasian post-MI patients are impacted by CYP2C19 genotype, and suggest knowledge of genotype may be useful for personalizing PPI use among patients following AMI to reduce rehospitalization. |
format | Online Article Text |
id | pubmed-4287459 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
record_format | MEDLINE/PubMed |
spelling | pubmed-42874592015-08-01 Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction Depta, Jeremiah P. Lenzini, Petra A. Lanfear, David E. Wang, Tracy Y. Spertus, John A. Bach, Richard G. Cresci, Sharon Pharmacogenomics J Article We examined clinical outcomes with proton pump inhibitors (PPI) use within CYP2C19 genotype groups during clopidogrel treatment following acute myocardial infarction (AMI). 2062 patients were genotyped for CYP2C19*2 and *17 variants in TRIUMPH. 12 month clinical outcomes were analyzed among patients discharged on clopidogrel within CYP2C19*2 carrier, CYP2C19*17 carrier, and CYP2C19*1 homozygote genotype groups. PPI use was not associated with a difference in mortality. Among clopidogrel-treated Caucasians following AMI, PPI use was associated with a significantly higher rate of cardiac rehospitalization (HR 1.62, 95% CI 1.19-2.19; p = 0.002) compared with no PPI use. PPI users who were carriers of the CYP2C19*17 variant experienced significantly higher rates of cardiac rehospitalization (HR 2.05, 95% CI 1.26-3.33; p = 0.003), carriers of the CYP2C19*2 variant had a trend toward increased 1-year cardiac rehospitalization (HR 1.69, 95% CI 0.95-2.99; P=0.07) while no significant differences were observed among CYP2C19*1 homozygotes. These results indicate that the risks associated with PPI use among clopidogrel-treated Caucasian post-MI patients are impacted by CYP2C19 genotype, and suggest knowledge of genotype may be useful for personalizing PPI use among patients following AMI to reduce rehospitalization. 2014-07-08 2015-02 /pmc/articles/PMC4287459/ /pubmed/25001880 http://dx.doi.org/10.1038/tpj.2014.28 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Depta, Jeremiah P. Lenzini, Petra A. Lanfear, David E. Wang, Tracy Y. Spertus, John A. Bach, Richard G. Cresci, Sharon Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction |
title | Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction |
title_full | Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction |
title_fullStr | Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction |
title_full_unstemmed | Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction |
title_short | Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction |
title_sort | clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within cyp2c19 genotype groups following acute myocardial infarction |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287459/ https://www.ncbi.nlm.nih.gov/pubmed/25001880 http://dx.doi.org/10.1038/tpj.2014.28 |
work_keys_str_mv | AT deptajeremiahp clinicaloutcomesassociatedwithprotonpumpinhibitoruseamongclopidogreltreatedpatientswithincyp2c19genotypegroupsfollowingacutemyocardialinfarction AT lenzinipetraa clinicaloutcomesassociatedwithprotonpumpinhibitoruseamongclopidogreltreatedpatientswithincyp2c19genotypegroupsfollowingacutemyocardialinfarction AT lanfeardavide clinicaloutcomesassociatedwithprotonpumpinhibitoruseamongclopidogreltreatedpatientswithincyp2c19genotypegroupsfollowingacutemyocardialinfarction AT wangtracyy clinicaloutcomesassociatedwithprotonpumpinhibitoruseamongclopidogreltreatedpatientswithincyp2c19genotypegroupsfollowingacutemyocardialinfarction AT spertusjohna clinicaloutcomesassociatedwithprotonpumpinhibitoruseamongclopidogreltreatedpatientswithincyp2c19genotypegroupsfollowingacutemyocardialinfarction AT bachrichardg clinicaloutcomesassociatedwithprotonpumpinhibitoruseamongclopidogreltreatedpatientswithincyp2c19genotypegroupsfollowingacutemyocardialinfarction AT crescisharon clinicaloutcomesassociatedwithprotonpumpinhibitoruseamongclopidogreltreatedpatientswithincyp2c19genotypegroupsfollowingacutemyocardialinfarction |